Evidence map›Paper›PMID 41484513›Full record

Trial reportProbiotics and antimicrobial proteins2026

Probiotic-Containing Nanofiber-Based Dental Floss Suppresses Subgingival Red Complex Periopathogens: A Randomized Double-Blind Crossover Trial.

Filip Hromcik, Pavla Holochova, Jan Bohm, Eva Kuzelova Kostakova, Zdenek Pokorny, Filip Ruzicka, Petra Borilova Linhartova

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07149493 (Probiotic-containing Nanofiber-based Dental Floss Suppresses Subgingival Red Complex Periopathogens), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07149493 nacompletednot on this map

Probiotic-containing Nanofiber-based Dental Floss Suppresses Subgingival Red Complex Periopathogens: A Randomized Double-blind Crossover Study

TypeinterventionalSponsorSt. Anne's University Hospital Brno, Czech RepublicRan2022 to 2022Enrolled33ConditionsDental Hygiene, Probiotics, Periodontitis, Prevention of Dental Caries, Gingivitis and Periodontal DiseasesArmsPlacebo nanofiber floss, Probiotic nanofiber floss
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Filip HromcikClinic of Stomatology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.ORCID http://orcid.org/0000-0001-9859-3198
Pavla HolochovaFaculty of Science, RECETOX, Masaryk University, Kotlarska 2, 60200, Brno, Czech Republic.ORCID http://orcid.org/0000-0003-1122-4125
Jan BohmFaculty of Science, RECETOX, Masaryk University, Kotlarska 2, 60200, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-9723-9493
Eva Kuzelova KostakovaDepartment of Chemistry, Faculty of Science, Humanities and Education, Technical University of Liberec, Studentska 2, Liberec, 46117, Czech Republic.ORCID http://orcid.org/0000-0002-5758-3206
Zdenek PokornyDepartment of Mechanical Engineering, Faculty of Military Technology, University of Defence, Kounicova 65, Brno, 61200, Czech Republic.ORCID http://orcid.org/0000-0002-7098-3693
Filip RuzickaInstitute of Microbiology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic.ORCID http://orcid.org/0000-0001-5679-0513
Petra Borilova LinhartovaClinic of Stomatology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Pekarska 53, Brno, 60200, Czech Republic. petra.linhartova@recetox.muni.cz.ORCID http://orcid.org/0000-0003-0953-3615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, a dental nanofloss containing a probiotic (Ligilactobacillus salivarius; LS-nanofloss) was developed by our team. This study aimed to evaluate: (i) its impact on subgingival plaque accumulation and gingival bleeding, and (ii) retention of selected subgingival periopathogens and the introduced probiotic bacteria, and (iii) its effect on the quantity of red complex periopathogens in the subgingival environment. This randomized, double-blind, crossover trial was conducted in 30 healthy male participants. Each subject underwent professional flossing and subsequently used LS-nanofloss/probiotic-free (control) nanofloss at two separate 14-day periods, always followed by a 14-day wash-out. Clinical assessments (subgingival plaque accumulation and gingival bleeding) were performed at five time points; subgingival plaque samples were collected at seven time points for quantitative analysis of total bacterial DNA, L. salivarius, a cariogenic bacterium Streptococcus mutans, and red complex periopathogens. Both nanofloss types significantly reduced plaque accumulation and gingival bleeding after 14 days (p < 0.05), especially in the anterior regions; these improvements, however, regressed after the wash-out period. L. salivarius DNA was detected in 93.3% of samples after professional flossing, 36.7% after self-flossing, and 13.3% even after the wash-out period. The use of LS-nanofloss was associated with a significant reduction in red complex periopathogens (p < 0.05). The investigated L. salivarius-containing nanofloss proved to be an effective oral hygiene device for subgingival introduction of this probiotic strain. Its application reduced the relative quantity of red complex periopathogens in the subgingival environment, showing potential to prevent the development of periodontitis. The trial was registered retrospectively on 2/9/2025 as NCT07149493.

Indexed as

Dental Devices, Home CareDental PlaqueNanofibersProbioticsAdultCross-Over StudiesDouble-Blind MethodHumansMaleStreptococcus mutansStreptococcus salivariusYoung AdultDental devicesDysbiosisLactobacillusNanotechnologyOral healthProbiotics

Identifiers

PMID41484513
PMCPMC13369690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.